Du, H., Rao, Y., Liu, R., Deng, K., Guan, Y., Luo, D., Mao, Q., Yu, J., Bo, T., Fan, Z., Ouyang, H., Feng, Y., and Zhu, W., Proteomics and metabolomics analyses reveal the full spectrum of inflammatory and lipid metabolic abnormalities in dyslipidemia, Biomed. Chromatogr., 2021, vol. 35, no. 10, p. e5183. https://doi.org/10.1002/bmc.5183
Article CAS PubMed Google Scholar
Poznyak, A.V., Kashirskikh, D.A., Sukhorukov, V.N., Kalmykov, V., Omelchenko, A.V., and Orekhov, A.N., Cholesterol transport dysfunction and its involvement in atherogenesis, Int. J. Mol. Sci., 2022, vol. 23, no. 3, p. 1332. https://doi.org/10.3390/ijms23031332
Article CAS PubMed PubMed Central Google Scholar
Nordestgaard, B.G. and Varbo, A., Triglycerides and cardiovascular disease, Lancet, 2014, vol. 384, no. 9943, pp. 626–635. https://doi.org/10.1016/S0140-6736(14)61177-6
Article CAS PubMed Google Scholar
Park, M.S., Youn, J.C., Kim, E.J., Han, K.H., Lee, S.H., Kim, S.H., Kim, B.J., Kwon, S.U., and Ryu, K.H., Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy: A multicenter, randomized, double-blind, phase IV study, Clin. Ther., 2021, vol. 43, no. 10, pp. 1735–1747. https://doi.org/10.1016/j.clinthera.2021.08.005
Article CAS PubMed Google Scholar
Zhang, Z.J., Yuan, Y.H., Ma, M.S., Hong, Y.H., Sun, Z.X., Xu, Y.W., Wei, M., and Qiu, Z.Q., Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I, Eur. Rev. Med. Pharmacol. Sci., 2020, vol. 24, no. 19, pp. 10036–10044. https://doi.org/10.26355/eurrev_202010_23218
Tanaka, H., Ishida, T., Johnston, T.P., Yasuda, T., Ueyama, T., Kojima, Y., Kundu, R.K., Quertermous, T., Ishikawa, Y., and Hirata, K., Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia, J. Atheroscler. Thromb., 2009, vol. 4, pp. 327–338. https://doi.org/10.5551/jat.no844
Casula, M., Colpani, O., Xie, S., Catapano, A.L., and Baragetti, A., HDL in atherosclerotic cardiovascular disease: In search of a role, Cells, 2021, vol. 10, no. 8, p. 1869. https://doi.org/10.3390/cells10081869
Article CAS PubMed PubMed Central Google Scholar
Stoekenbroek, R.M., Boekholdt, S.M., Fayyad, R., Laskey, R., Tikkanen, M.J., Pedersen, T.R., and Hovingh, G.K., Incremental decrease in end points through aggressive lipid lowering study group, high-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease, Heart, 2015, vol. 101, no. 5, pp. 356–362. https://doi.org/10.1136/heartjnl-2014-306906
Article CAS PubMed Google Scholar
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G.D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., and Peto, R., Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 2016, vol. 388, no. 10059, pp. 2532–2561. https://doi.org/10.1016/S0140-6736(16)31357-5
Article CAS PubMed Google Scholar
Jang, A.Y., Lim, S., Jo, S.H., Han, S.H., and Koh, K.K., New trends in dyslipidemia treatment, Circ. J., 2021, vol. 85, no. 6, pp. 759–768. https://doi.org/10.1253/circj.CJ-20-1037
Article CAS PubMed Google Scholar
Paraskevas, K.I., Pantopoulou, A., Vlachos, I.S., Agrogiannis, G., Iliopoulos, D.G., Karatzas, G., Tzivras, D., Mikhailidis, D.P., and Perrea, D.N., Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model, Angiology, 2011, vol. 62, no. 2, pp. 144–154. https://doi.org/10.1177/0003319710387919
Article CAS PubMed Google Scholar
Davidson, M.H., Rooney, M.W., Drucker, J., Eugene Griffin, H., Oosman, S., Beckert, M., LCP-AtorFen Investigators, Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double blind, randomized, parallel-group study, Clin. Ther., 2009, vol. 31, no. 12, pp. 2824–2838. https://doi.org/10.1016/j.clinthera.2009.12.007
Article CAS PubMed Google Scholar
Harivenkatesh, N., David, D.C., Haribalaji, N., and Sudhakar, M.K., Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: A randomized controlled trial, J. Cardiovasc. Pharmacol. Ther., 2014, vol. 19, no. 3, pp. 296–303. https://doi.org/10.1177/1074248413518968
Article CAS PubMed Google Scholar
Enger, C., Gately, R., Ming, E.E., Niemcryk, S.J., Williams, L., and McAfee, A.T., Pharmacoepidemiology safety study of fibrate and statin concomitant therapy, Am. J. Cardiol., 2010, vol. 106, no. 11, pp. 1594–1601. https://doi.org/10.1016/j.amjcard.2010.07.041
Article CAS PubMed Google Scholar
Flores-Castillo, C., Zamora-Pérez, J.Á., Carreón-Torres, E., Arzola-Paniagua, A., Aguilar-Salinas, C., López-Olmos, V., Fragoso, J.M., Luna-Luna, M., Rodríguez-Pérez, J.M., Franco, M., Vargas-Alarcón, G., and Pérez-Méndez, Ó., Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia, Fundam. Clin. Pharmacol., 2015, vol. 29, no. 4, pp. 362–370. https://doi.org/10.1111/fcp.12125
Article CAS PubMed Google Scholar
Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H., Choi, I.S., and Shin, E.K., Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia, J. Am. Coll. Cardiol., 2005, vol. 45, no. 10, pp. 1649–1653. https://doi.org/10.1016/j.jacc.2005.02.052
Article CAS PubMed Google Scholar
Johnston, T.P., Korolenko, T.A., and Sahebkar, A., The P-407-induced mouse model of dose-controlled hyperlipidemia and atherosclerosis: Twenty-five years later, J. Cardiovasc. Pharmacol., 2017, vol. 70, no. 5, pp. 339–352. https://doi.org/10.1097/FJC.0000000000000522
Article CAS PubMed Google Scholar
Arca, M., Montali, A., Pigna, G., Antonini, R., Antonini, T.M., Luigi, P., Fraioli, A., Mastrantoni, M., Maddaloni, M., and Letizia, C., Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia, Metabolism, 2007, vol. 56, no. 11, pp. 1534–1541. https://doi.org/10.1016/j.metabol.2007.06.021
Article CAS PubMed Google Scholar
Zhu, Y., Zhang, H.P., Wang, Y.C., Ren, T.T., Li, J., Xu, M.L., Wang, X.Q., Liu, F.C., Lau, A., and Wen, Y.F., Serum cystatin C level is associated with carotid intima-media thickening and plaque, Scand. J. Clin. Lab. Invest., 2015, vol. 75, no. 3, pp. 265–272. https://doi.org/10.3109/00365513.2015.1006137
Article CAS PubMed Google Scholar
Grubb, A., Blirup-Jensen, S., Lindström, V., Schmidt, C., Althaus, H., Zegers, I., IFCC Working Group on Standardisation of Cystatin C (WG-SCC), First certified reference material for cystatin C in human serum ERM-DA471/IFCC, Clin. Chem. Lab. Med., 2010, vol. 48, no. 11, pp. 1619–1621. https://doi.org/10.1515/CCLM.2010.318
Article CAS PubMed Google Scholar
Korolenko, T.A., Cherkanova, M.S., Gashenko, E.A., Johnston, T.P., and Bravve, I.Y., Cystatin C, atherosclerosis and lipid-lowering therapy by statins, in Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators, Cohen, J.B. and Rysek, L.P., Eds., New York: Nova Science, 2011, pp. 187–204.
Korolenko, T.A., Pisareva, E.E., Filyushina, E.E., Johnston, T.P., and Machova, E., Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: Can they serve as potential early biomarkers for atherosclerosis?, Exp. Toxicol. Pathol., 2015, vol. 67, no. 9, pp. 459–466. https://doi.org/10.1016/j.etp.2015.06.003
Article CAS PubMed Google Scholar
Ge, C.J., Lü, S.Z., Feng, L.X., Huo, Y., Song, X.T., Chen, X., Meng, K., and Yuan, F., Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion, Chin. Med. J. (Beijing, China, E-ngl. Ed.), 2012, vol. 125, no. 14, pp. 2472–2476.
Wallin, H., Abrahamson, M., and Ekström, U., Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes, J. Biol. Chem., 2013, vol. 288, no. 23, pp. 17019–17029. https://doi.org/10.1074/jbc.M113.453449
Article CAS PubMed PubMed Central Google Scholar
Stankute, I., Radzeviciene, L., Monstaviciene, A., Dobrovolskiene, R., Danyte, E., and Verkauskiene, R., Serum cystatin C as a biomarker for early diabetic kidney disease and dyslipidemia in young type 1 diabetes patients, Medicina (Kaunas), 2022, vol. 58, no. 2, p. 218. https://doi.org/10.3390/medicina58020218
Article PubMed PubMed Central Google Scholar
Chen, X., Huang, Y., Bao, T., Jia, F., Ou, R., Wei, Q., Chen, Y., Liu, J., Yang, J., and Shang, H., Changes in serum cystatin C levels and the associations with cognitive function in Alzheimer’s disease patients, Front. Aging Neurosci., 2022, vol. 13, p. 790939. https://doi.org/10.3389/fnagi.2021.790939
Article CAS PubMed PubMed Central Google Scholar
Keppler, D., Towards novel anti-cancer strategies based on cystatin function, Cancer Lett., 2006, vol. 235, no. 2, pp. 159–176. https://doi.org/10.1016/j.canlet.2005.04.001
留言 (0)